Skip to main content
SpringerLink
Log in

Biomedical hydrogels

A defensive blanket against viral infection of the lungs

  • News & Views
  • Published:

From Nature Materials

View current issue Submit your manuscript

A safe, inhalable formulation of mucin-interacting hydrogel microparticles creates a dense protective network in the lungs against viral infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Overview of the SHIELD treatment.

References

  1. Mowat, A. M. & Viney, J. L. Immunol. Rev. 156, 145–166 (1997).

    Article  CAS  Google Scholar 

  2. Gehr, P., Bachofen, M. & Weibel, E. R. Respir. Physiol. 32, 121–140 (1978).

    Article  CAS  Google Scholar 

  3. Cone, R. A. Adv. Drug Deliv. Rev. 61, 75–85 (2008).

    Article  Google Scholar 

  4. Mei, X. et al. Nat. Mater. https://doi.org/10.1038/s41563-023-01475-7 (2023).

    Article  Google Scholar 

  5. Leech, G. et al. Proc. Natl Acad. Sci. USA 119, e2119266119 (2022).

    Article  CAS  Google Scholar 

  6. Bergeron, C. & Cantin, A. M. Semin. Respir. Crit. Care Med. 40, 715–726 (2019).

    Article  Google Scholar 

  7. Carlson, T. L., Lock, J. Y. & Carrier, R. L. Annu. Rev. Biomed. Eng. 20, 197–220 (2018).

    Article  CAS  Google Scholar 

  8. Chemaly, R. F. et al. Clin. Infect. Dis. 73, e773–e781 (2021).

    Article  CAS  Google Scholar 

  9. Schimpf, U. et al. Sci. Transl Med. 14, eabm2417 (2022).

    Article  CAS  Google Scholar 

  10. Crouzier, T. et al. Adv. Mater. Interfaces 2, 1500308 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Glycoscience, Department of Chemistry, School of Engineering Science in Chemistry, Biotechnology and Health (CBH), AlbaNova University Center, KTH Royal Institute of Technology, Stockholm, Sweden

    Thomas Crouzier

  2. Cirqle Biomedical Contraception ApS, Copenhagen, Denmark

    Thomas Crouzier

  3. AIMES—Center for the Advancement of Integrated Medical and Engineering Sciences, Karolinska Institutet and KTH Royal Institute of Technology, Stockholm, Sweden

    Thomas Crouzier

  4. Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden

    Thomas Crouzier

Authors
  1. Thomas Crouzier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Crouzier.

Ethics declarations

Competing interests

T.C. is co-founder, shareholder, and acting chief scientific officer of Cirqle Biomedical Contraception ApS, a company developing a contraceptive through the topical reinforcement of cervical mucus.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crouzier, T. A defensive blanket against viral infection of the lungs. Nat. Mater. 22, 803–804 (2023). https://doi.org/10.1038/s41563-023-01594-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41563-023-01594-1

  • Springer Nature Limited

Search

Navigation